Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: A randomized, double-blind multicenter study

JAMA

Volumn 277, Issue 13, 1997, Pages 1046-1051

  Low, Phillip A ^a   Gilden, Janice L ^b   Freeman, Roy ^c   Sheng, Ke Ning ^d   McElligott, Mary Ann ^d  

^a MAYO CLINIC   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Roberts Pharmaceutical Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUDROCORTISONE ACETATE; MIDODRINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; URINE RETENTION; VASOMOTOR REFLEX; VERTIGO;

EID: 0031004940     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.13.1046     Document Type: Article

References (16)

1. Low PA, McLeod JG. The autonomie neuropathies. In: Low PA, ed. Clinical Autonomic Disorders: Evaluation and Management. Boston, Mass: Little Brown & Co Inc; 1993:395-421.
2. Bannister R. Multiple system atrophy and pure autonomie failure. In: Low PA, ed. Clinical Autonomic Disorders: Evaluation and Management. Boston, Mass: Little Brown & Co Inc; 1993:517-526.
3. Thomas JE, Schirger A. Idiopathic orthostatic hypotension: a study of its natural history in 57 neurologically affected persons. Arch Neurol. 1970; 22:289-293.
4. Cohen J, Low P, Fealey R, Sheps S, Jiang N-S. Somatic and autonomie function in progressive autonomic failure and multiple system atrophy. Ann Neurol. 1987;22:692-699.
5. Fealey RD, Robertson D. Management of orthostatic hypotension. In: Low PA, ed. Clinical Autonomic Disorders: Evaluation and Management. Boston, Mass: Little Brown & Co Inc; 1993: 731-743.
6. Grobecker H, Kees F, Linden M, Schrader E, Weite S. Studies on the bioavailability of midodrine and alpha-2,5-dimethoxyphenyl-beta-aminoethanol-hydrochloride. Arzneimittelforschung. 1987;37:447-450.
7. McTavish D, Goa KL. Midodrine: a review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs. 1989;38:757-777.
8. Zachariah PK, Bloedow DC, Moyer TP, Sheps SG, Schirger A, Fealey RD. Pharmacodynamics of midodrine, an antihypotensive agent. Clin Pharmacol Ther. 1986;39:586-591.
9. Thulesius O, Gjores JE, Berlin E. Vasoconstrictor effect of midodrine, ST 1059, noradrenaline, etilefrine, and dihydroergotamine on isolated human veins. Eur J Clin Pharmacol 1979;16:423-424.
10. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind placebo-controlled study with midodrine. Am J Med. 1993;95:38-48.
11. Robertson D, Davis TL. Recent advances in the treatment of orthostatic hypotension. Neurology. 1995;45(suppl 5):S26-S32.
12. Wright A, Opfer-Gehrking TL, McElligott MA, Low PA. Double-blind, randomized dose-response study of midodrine in patients with neurogenic orthostatic hypotension. Neurology. 1995;45(suppl): A396-A397. Abstract.
13. Sandroni P, Ahlskog JE, Fealey RD, Low PA. Autonomic involvement in extrapyramidal and cerebellar disorders. Clin Auton Res. 1991;1:147-155.
14. Low PA, Opfer-Gehrking TL, Textor SC, et al. Postural tachycardia syndrome (POTS). Neurology, 1995;45(suppl 5):S19-S25.
15. Dobkin BH. Orthostatic hypotension as a risk factor for symptomatic occlusive cerebrovascular disease. Neurology. 1989;39:30-34.
16. Thomas DJ, Bannister R. Preservation of autoregulation of cerebral blood flow in autonomic failure. J Neurol Sci. 1980;44:205-212.